Treatment of daytime urinary incontinence: A standardization document from the International Children's Continence Society

Neurourol Urodyn. 2017 Jan;36(1):43-50. doi: 10.1002/nau.22911. Epub 2015 Oct 16.

Abstract

Purpose: This article is a standardization document of the International Children's Continence Society (ICCS); it represent a consensus of ICCS on the management of pediatric daytime urine incontinence (DUI).

Materials and methods: This document was designed and written by a multi-disciplinary core group of authors appointed by the ICCS' board.

Results: Based on evidence of studies and the experience of experts, the treatment guideline of DUI is assembled in this standardization document. Guidelines and the algorithm of management include non-pharmacological treatment (urotherapy), as well as the pharmacological therapy and other modalities that are presented for DUI in general, as along with recommendations for individual conditions.

Conclusion: The final document is not a systematic literature review. It includes relevant research when available as well as experts' opinion on the current understanding of daytime incontinence in children. This document illustrates that specific treatment of DUI based on an exact diagnosis is effective. The mainstay of treatment is urotherapy, but a combination of treatment modalities is often necessary. Neurourol. Urodynam. 36:43-50, 2017. © 2015 Wiley Periodicals, Inc.

Keywords: child; daytime incontinence; non-pharmacological treatment; pharmacological treatment; urotherapy.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Adrenergic alpha-Antagonists / therapeutic use
  • Algorithms
  • Botulinum Toxins / therapeutic use
  • Child
  • Consensus
  • Conservative Treatment
  • Humans
  • Muscarinic Antagonists / therapeutic use
  • Reference Standards
  • Urinary Incontinence / drug therapy
  • Urinary Incontinence / etiology
  • Urinary Incontinence / therapy*
  • Urinary Incontinence, Urge / drug therapy
  • Urinary Incontinence, Urge / therapy

Substances

  • Adrenergic alpha-Antagonists
  • Muscarinic Antagonists
  • Botulinum Toxins